Atezolizumab for the treatment of triple-negative breast cancer

  title={Atezolizumab for the treatment of triple-negative breast cancer},
  author={Anne-Sophie Heimes and Marcus Schmidt},
  journal={Expert Opinion on Investigational Drugs},
  pages={1 - 5}
ABSTRACT Introduction: Triple-negative breast cancer (TNBC) is associated with poor prognosis and limited treatment options. However, TNBC is known to be more immunogenic compared to other breast cancer subtypes, with tumor-infiltrating lymphocytes playing an important prognostic and predictive role. Furthermore, TNBC has a higher level of programmed cell death-ligand 1 (PD-L1) expression. Therapeutic blockade of PD-L1 using atezolizumab is thus expected to activate and enhance tumor-specific T… 

Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions

This review summarizes the clinical data supporting the use of atezolizumab and nab-paclitaxel in the treatment of metastatic PD-L1-positive TNBC and examines the pharmacology and toxicity profile of the combination in patients with metastatic TNBC.

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer

Atezolizumab plus nab-paclitaxel represents a potential new first-line standard of care for patients with metastatic PD-L1-positive TNBC and other ICIs used as monotherapy, or combined with chemotherapy for advanced TNBC, as well as their use for earlier stage disease.

Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.

The importance of this breakthrough as the first cancer immunotherapy regimen to be approved for the management of breast cancer is discussed.

Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond

Potential predictors of response to ICIs in breast cancer, including PD-L1 expression, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and several other biomarkers are discussed and future directions of research in this setting are suggested.

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

This review assesses the latest developments in basic characterization, subtyping, and treatment of triple negative breast cancer, including novel drug developments with antibody-drug conjugates, immune checkpoint inhibitors, PARP inhibitors and androgen receptor targeted agents.

The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer

Triple-Negative Breast Cancer (TNBC) is characterised by worse outcomes, including higher risks of relapse and visceral crisis compared to other BC subtypes (especially during the first 2 years post BC diagnosis).

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

An updated overview of potentially useful predictive biomarkers of response to immunotherapy in advanced HCC patients is provided, a literature search was conducted in September 2021 of Pubmed/Medline, Cochrane library and Scopus databases.

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

2 other PD-L1 assays are evaluated for analytical concordance with SP142 and patient-associated clinical outcomes and consistent improved A+nP efficacy was captured by the SP142 PD- l1 IC ≥1% subgroup nested within 22C3 and SP263 PD- L1+ (IC ≥1%) populations.

Immunotherapy for Breast Cancer: First FDA Approved Regimen

This immunotherapy-based regimen comprising atezolizumab in combination with protein-bound paclitaxel for patients with advanced metastatic TNBC, expressing programmed cell death-ligand 1 (PD-L1) and without previous systemic treatment for metastatic disease is not only a promising therapy for the TNBC patients, but it also represents an inspiring proof of concept for the development of more efficient advanced immun therapy-based strategies for breast cancer treatment in the future.

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

The potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.



Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  • R. NandaL. Chow L. Buisseret
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC, and showed an acceptable safety profile and clinical activity in a subset of patients with MBC.

Dissecting the heterogeneity of triple-negative breast cancer.

The biology of TNBC at the pathologic and the molecular levels is discussed and the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib are elaborate.

Breast Cancer Immunotherapy: Facts and Hopes

  • L. Emens
  • Medicine, Biology
    Clinical Cancer Research
  • 2017
Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer

The findings suggest that TNBC is a breast cancer subtype with particularly strong immunogenicity, and therefore could be propitious to immunotherapeutic options.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile and biomarker responses were observed, including in patients previously treated with a taxane.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.

  • F. AndréC. Zielinski
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
The newly approved agent eribulin has shown a survival benefit in patients who had previously been treated with anthracycline- or taxane-containing regimens, including in patients with TNBC.

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.